Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Summary:
- RSI is at a high level of 72. A high level of RSI indicates the stock is overbought.
- MACD is crossing MACD signal line at 0.4. MACD crossing signal line is bullish signal.
| MarketCap | 421.2M |
|---|---|
| PE Ratio | -6.2 |
| PEG Ratio | -0.1 |
| P/B | 11.6 |
| P/S (ttm) | 7.4 |
| Earning Growth (QoQ) | |
| Revenue Growth (QoQ) | |
| Short % | 15% |
| Held by Institutions % | 23% |
| 1 Day Vol Adjusted Return | 0.2 |
| 1 Month Vol Adjusted Return | 5.4 |
| 3 Month Vol Adjusted Return | 21.1 |
| 6 Month Vol Adjusted Return | 23.7 |
| 20 Days SMA Price ZScore | 1.8 |
| 50 Days SMA Price ZScore | 2.4 |
| 12 -26 Days PPO | 18.7 |
| 1 Month Average Short Volume Ratio | 47.3 |
| 1 Day Volume Change ZScore | -0.3 |
| 1 Month Daily Vol | 16.9 |
Stock news
Evolus (EOLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
NEWPORT BEACH, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced the promotion of Crystal Muilenburg from VP, Corporate Communications & PR to Chief Marketing Officer effective today. Crystal will oversee the U.S. marketing organization and establish the company’s international infrastructure to support the expansion of Nuceiva™ in all Evolus licensed te...
Q4 2020 Net Revenue of $20.6 Million Increased 16% Over Q3 2020NEWPORT BEACH, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS) today announced its preliminary, unaudited, net revenues for the fourth quarter and full year ended December 31, 2020. The preliminary unaudited results described in this press release are estimates only and are subject to revision until the company reports its full financial results for the fourth quarter and full year 2020. “We delivered another qu...
Evolus (NASDAQ:EOLS) stock was on the rise Friday following news that it’s no longer dealing with lawsuits from AbbVie (NYSE:ABBV) and Medytox. Source: Bukhta Yurii / Shutterstock.com The legal battle between the companies was over Evolus selling Jeuveau. This is a prescription drug that is injected into muscles to temporarily reduce severe lines around the eyes. The allegations claimed that Evolus misused trade secrets for Jeuveau. The news today is that AbbVie and Medytox are dropping all clai...
NEWPORT BEACH, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of management will be participating in the 10th Annual SVB Leerink Global Healthcare Conference. Event: 10th Annual SVB Leerink Global Healthcare Conference Format: Fireside Chat & 1x1 Meetings Date: Wednesday, February 24, 2021 Time: 1:00pm – 1:30pm ET Location: Evolus Live Fi...
Evolus Inc (NASDAQ: EOLS), AbbVie Inc (NYSE: ABBV), and Medytox announced settlement agreements to fully resolve all outstanding litigation, including the United States International Trade Commission (ITC) case regarding the sale of Jeuveau. It is a prescription medicine injected into muscles and used in adults temporarily to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines). A California court case filed by Medytox against Evolus will be dismissed. Under ...
AbbVie (NYSE: ABBV), Evolus (NASDAQ: EOLS) and Medytox announce settlement agreements to fully resolve all outstanding litigation, including the United States International Trade Commission (ITC) case regarding the sale of Jeuveau®, between the companies. A California court case filed by Medytox against Evolus will be dismissed.
Evolus, Inc. ( NASDAQ:EOLS ) is possibly approaching a major achievement in its business, so we would like to shine...